

sought with experience and success in activities specified in the summary paragraph above, through which the Agency carries out its work.

**DATES:** Nominations should be received on or before July 13, 2001.

**ADDRESSES:** Nominations should be sent to Ms. Anne Lebbon, AHRQ, 2101 East Jefferson Street, Suite 600, Rockville, Maryland 20852. Nominations also may be faxed to (301) 443-0251.

**FOR FURTHER INFORMATION CONTACT:** Ms. Anne Lebbon, AHRQ, at (301) 594-7216.

**SUPPLEMENTARY INFORMATION:** 42 U.S.C. 299c, section 921 of the PHS Act, provides that the National Advisory Council for Health and Research and Quality shall consist of 21 appropriately qualified representatives of the public appointed by the Secretary of Health and Human Services and eight ex officio representatives from Federal agencies conducting or supporting health care research. The Council meets in the Washington, DC, metropolitan area, generally in Rockville, Maryland, approximately three times a year to provide broad guidance to the Secretary and AHRQ's Director on the direction and programs for AHRQ.

Seven individuals will presently be selected by the Secretary to serve on the Council beginning with the meeting in the fall of 2001. Members generally serve 3-year terms. Appointments are staggered to permit an orderly rotation of membership.

Interested persons may nominate one or more qualified persons for membership on the Council. Nominations shall include a copy of the nominee's resume or curriculum vitae, and state that the nominee is willing to serve as a member of the Council. Potential candidates will be asked to provide detailed information concerning their financial interests, consultant positions, and research grants and contracts, to permit evaluation of possible sources of conflict of interest.

The Department is seeking a broad geographic representation and has special interest in assuring that women, minority groups, and the physically handicapped and are adequately represented on advisory bodies and, therefore, extends particular encouragement to nominations for appropriately qualified female, minority, and/or physically handicapped candidates.

Dated: June 12, 2001.

**John M. Eisenberg,**

*Director,*

[FR Doc. 01-15665 Filed 6-21-01; 8:45 am]

**BILLING CODE 4160-90-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Administration on Aging

#### Agency Information Collection Activities: Proposed Submission to the Office of Management and Budget (OMB) for Clearance; Comment Request; Reinstatement of Previously Approved Information Collection

**AGENCY:** Administration on Aging, HHS.

The Administration on Aging (AoA), Department of Health and Human Services, provides an opportunity for comment on the following proposal for the collection of information in compliance with the Paperwork Reduction Act (PRA; Pub. L. 96-511):

*Title of Information Collection:* Reporting Requirements for the Alzheimer's Disease Demonstration Grants to States Program and GPRA data.

*Type of Request:* Reinstatement of a previously approved collection for which approval has expired.

*Use:* Data on persons served, services provided, and program staff will be collected semi-annually from participants in the Alzheimer's Disease Demonstration Grants to States Program. Data will be used for program modification and evaluation, annual Department reports, and a final report to Congress as set forth by congressional statute.

*Frequency:* Semi-annually.

*Respondents:* Agencies of State Governments that have been designated by the governor as the sole applicant for the State and who have applied for a grant under this program.

*Estimated Number of Responses:* 50/year.

*Total Estimated Burden Hours:* 1,000/year.

*Additional Information or Comments:* The Administration on Aging plans to submit to the Office of Management and Budget for reinstatement of a previously approved collection for which approval has expired, for the Alzheimer's Disease Demonstration Grants to States Program, pursuant to requirements set forth by congressional statute. Written comments and recommendations for the proposed information collection should be sent within 60 days of the publication of this notice directly to the following address: Office of Program Development, Administration on Aging, Attention: Melanie Starns, 330 Independence Avenue, SW., Rm 4270, Washington, DC 20201.

Dated: June 18, 2001.

**Norman L. Thompson,**

*Acting Principal Deputy Assistant Secretary for Aging.*

[FR Doc. 01-15728 Filed 6-21-01; 8:45 am]

**BILLING CODE 4154-01-U**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

#### Request for Interest in Participating in the Selection of the Nonvoting Members of Industry Interests on Public Advisory Committees; Nonprescription Drugs Advisory Committee

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is filling the position of nonvoting industry representative on the Nonprescription Drugs Advisory Committee. FDA requests that any industry organization, that is interested in participating in the selection of an appropriate nonvoting member of the Nonprescription Drugs Advisory Committee to represent industry, send a letter stating that interest to the FDA employee designated below within 30 days of the date of this notice. In addition, if individuals or organizations would like to nominate individuals to serve as the nonvoting industry representative, they may do so.

**DATES:** Letters of interest and nominations should be received on or before July 23, 2001.

**ADDRESSES:** All nominations for membership should be submitted to Sandra Titus (address below).

**FOR FURTHER INFORMATION CONTACT:** Sandra Titus, Advisors and Consultants Staff (HFD-21), Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-7001, e-mail: tituss@cder.fda.gov.

#### **SUPPLEMENTARY INFORMATION:**

##### **I. Function**

The function of the committee is to review and evaluate available data concerning the safety and effectiveness of over-the-counter (nonprescription) human drug products for use in the treatment of a broad spectrum of human symptoms and diseases.

##### **II. Selection Procedure**

Any industry organization interested in participating in the selection of an appropriate nonvoting member of the